News & Events
First treatment licensed for primary progressive MS in the US
Ocrelizumab has been approved as a treatment for both relapsing and primary progressive MS in the US
Neurofilament is related to disability and brain shrinkage in MS
Study suggests neurofilament levels may be used as a marker of damage to brain cells in MS
No link between oral contraceptive drugs and MS relapses
Use of oral hormonal contraceptive drugs does not appear to be associated with greater risk of relapses
CCSVI: Latest findings show no association to multiple sclerosis
The latest and most thorough studies do not show an association between CCSVI and MS
Long-term safety and effectiveness of fampridine
Researchers find fampridine safe and effective in the long term for improving walking speed
Lifestyle risk factors in the progression of multiple sclerosis
Low vitamin D levels and smoking consistently associated with MS progression
Applications for MSIF fellowships and grants now open
The deadline for applications for McDonald fellowships and Du Pré Grants is 30 June 2017
Cognitive impairment and sodium concentration in gray matter
Advanced MRI shows sodium concentration in gray matter better explains cognition than atrophy in MS
Early treatment benefits individuals with a first attack resembling MS
People diagnosed with CIS who received early treatment are less likely to convert to MS
A simple specialised eye examination can show the effect of MS drugs
Optical coherence tomography may be used to test the effect of drugs in relapsing-remitting MS trials
Early evidence of multiple sclerosis in high risk family members
Some family members of people with MS show possible early signs of the disease without symptoms
Biomarker for predicting MS risk after clinically isolated syndrome
A biomarker in cerebrospinal fluid is associated with a higher risk of MS in people with CIS